(MedPage Today) — The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals announced on Thursday.
A rare, progressive neurodegenerative…
Source link : https://www.medpagetoday.com/ophthalmology/generalophthalmology/114553
Author :
Publish date : 2025-03-07 22:02:00
Copyright for syndicated content belongs to the linked Source.
